Inhibrx Biosciences

INBXPhase 3

Inhibrx leverages its proprietary sdAb platform to create differentiated, multi-specific protein therapeutics designed to overcome the limitations of conventional antibodies. The company's pipeline includes multiple clinical-stage assets targeting oncology and rare diseases, with strategic partnerships in place with major pharmaceutical companies. Inhibrx's approach focuses on optimizing pharmacokinetics, tissue penetration, and manufacturability to develop best-in-class therapies for complex biological targets.

Market Cap

$886.0M

Employees

100-250

Focus

Biotech

INBX · Stock Price

USD 60.92+48.41 (+387.10%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for engineering single-domain antibody (sdAb) fragments into multi-specific, Fc-fused protein therapeutics with optimized pharmacokinetics and tissue penetration.

Pipeline Snapshot

6 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
INBRX-106 + Pembrolizumab	Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2/3
INBRX-109 + Placebo	Conventional Chondrosarcoma	Phase 2
Pembrolizumab + INBRX-106	Triple Negative Breast Cancer	Phase 2
INBRX-105 - PDL1x41BB antibody + Pembrolizumab	Metastatic Solid Tumors	Phase 1
INBRX-101/rhAAT-Fc	Alpha-1 Antitrypsin Deficiency	Phase 1

Funding History

Total raised: $350M

IPO$150MUndisclosedJan 31, 2020

Series C$120MRA Capital ManagementDec 15, 2018

Series B$60MUndisclosedJun 15, 2016

Series A$20MUndisclosedJan 15, 2014

Opportunities

Significant opportunity to disrupt the AATD treatment paradigm with a more convenient, monthly therapy (INBRX-101).

The multi-specific oncology pipeline addresses high-value targets in the large immuno-oncology market, with potential for best-in-class profiles.

The platform technology offers additional value through future discovery partnerships.

Risk Factors

High risk of clinical trial failure for novel mechanisms.

Intense competition from larger pharmaceutical companies with greater resources.

Dependence on capital markets for funding as a pre-revenue company.

Competitive Landscape

Faces competition in AATD from plasma-derived therapy leaders (Grifols, Takeda, CSL Behring) and novel modality companies. In oncology, competes with numerous biopharma firms developing PD-1/L1 and costimulatory agonists. Platform competes with other fragment-based technology companies like Sanofi (Ablynx) and Molecular Partners.

Publications

Patents

Pipeline